Bioinformatic and mathematical modelling

© drimafilm, adobe.stock.com

In tumor research and clinical oncology, clinical data are increasingly being supplemented by high-dimensional molecular data, so-called multi-omics data. This enables a more comprehensive characterization of individual disease progression and better tailoring of various treatment options to patients. In addition, it is beneficial to combine and analyze this information together with data from high-throughput drug testing and imaging - one of the major challenges of modern medicine.

The Personalized Tumor Therapy department at Fraunhofer ITEM specializes in analyzing individual disseminated tumor cells. This results in bioinformatic challenges, the solution of which usually involves the development of our own customized analysis pipelines and methods. We have developed software applications for medical research and diagnostics, one of which is already used in daily laboratory routine. Legal requirements for data protection and data security play a key role and are complied with in our projects at all levels of data processing.

Offers

mutation analysis

Reading out therapy-relevant mutations

The detection of certain mutations in cancer-associated genes is a prerequisite for the selection of many targeted therapies. The FDA-approved »MSK-IMPACT« assay for tissue samples detects more than 400 cancer-associated genes and thus offers a valuable tool for therapy decisions.

Disseminated and circulating tumor cells are the cells of origin of metastases and often differ significantly from the cells of the primary tumor. It is therefore important to isolate individual cells and test them for mutations to diagnose and monitor the progression of the disease. As this is not possible with the original IMPACT assay, we at Fraunhofer ITEM in Regensburg, together with the University of Regensburg, have adapted the wet lab and bioinformatics methods for single cells and expanded it to include additional target genes and pharmacogenetic markers.

Contact

Jens  Warfsmann

Contact Press / Media

Dr. Jens Warfsmann

Division of Personalized Tumor Therapy

Phone +49 941 298480-28

Martin Hoffmann

Contact Press / Media

Dr. Martin Hoffmann

Division of Personalized Tumor Therapy

Phone +49 941 298480-28

Bernhard Michael Polzer

Contact Press / Media

Priv.-Doz. Dr. Bernhard Michael Polzer

Deputy Division Director Personalized Tumor Therapy & Head of Department of Bioinformatics and Clinical Translation

Christian Werno

Contact Press / Media

Dr. Christian Werno

Head of Department of Molecular and Functional Assays